局部晚期胰体尾癌质子放疗中手术间隔物置入的初步临床结果
本研究分析9例接受手术间隔物置入后行质子放疗的局部晚期胰体尾癌患者,评估间隔物置入手术的安全性和可行性,并通过剂量体积直方图分析评估间隔物对剂量学的影响。结果显示间隔物置入安全可行,可显著提高肿瘤靶区剂量覆盖,同时遵守胃肠道剂量约束,但部分患者出现胃肠道不良反应。
要点
- 手术间隔物置入在局部晚期胰体尾癌中相对安全且技术可行
- 间隔物置入可显著改善肿瘤靶区的剂量覆盖
- 需关注质子放疗后胃肠道溃疡和穿孔等不良反应
核心结论
- 在局部晚期胰体尾癌中,手术间隔物置入相对安全且技术可行,比较放疗计划显示间隔物置入似乎可改善靠近胃肠道的肿瘤的剂量分布。
研究设计与样本
- 本研究分析了9例接受手术间隔物置入及后续质子放疗的患者数据,评估间隔物置入手术的安全性和可行性,并通过剂量体积直方图分析评估间隔物置入前后的剂量学影响。
主要发现
- 手术间隔物置入和后续质子放疗在所有病例中均成功完成。
- 基于剂量体积直方图分析,手术间隔物置入显著改善了覆盖95%的大体肿瘤体积、平均剂量和最小剂量,以及临床靶体积和计划靶体积的剂量,同时遵守了胃肠道的剂量约束。
- 根据常见不良事件术语标准,2例患者(22.2%)分别在质子放疗后1个月和35个月发生胃肠道溃疡(2级),1例患者(11.1%)在质子放疗后4个月发生胃穿孔(4级)。
关键数值与推荐
- 手术间隔物置入显著改善了覆盖95%的大体肿瘤体积、平均剂量和最小剂量,以及临床靶体积和计划靶体积的剂量,同时遵守胃肠道剂量约束。
- 2例患者(22.2%)发生胃肠道溃疡(2级),1例患者(11.1%)发生胃穿孔(4级)。
临床怎么用
- 对于局部晚期胰体尾癌靠近胃肠道的患者,可考虑手术间隔物置入以改善质子放疗剂量分布,但需警惕胃肠道溃疡和穿孔风险。
局限性
- 本研究样本量小(9例),为初步临床结果,需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Particle radiotherapy has increasingly gained acceptance for locally advanced pancreatic cancers owing to superior tumor conformity and dosimetry compared to conventional photon radiotherapy. However, the close proximity of the pancreas to the stomach and duodenum leads to radiation-induced gastrointestinal toxicities, which hinder the delivery of curative doses to the tumor. To overcome this problem, a surgical spacer was placed between the tumor and gastrointestinal tract, and subsequent proton radiotherapy was performed in this study. METHODS: Data from 9 patients who underwent surgical spacer placement and subsequent proton radiotherapy were analyzed. The safety and feasibility of the spacer placement surgery were evaluated; the impact of the spacer on dosimetry was also assessed using dose volume histogram (DVH) analyses, before and after surgical spacer placement. RESULTS: Surgical spacer placement and subsequent proton radiotherapy were successfully completed in all cases. Surgical spacer placement significantly improved the dose intensity covering 95%, mean, and minimum doses for the gross tumor volume, and the clinical and planning target volume based on the DVH, while respecting the dose constraints of the gastrointestinal tract. Based on the Common Terminology Criteria for Adverse Events, two patients (22.2%) developed gastrointestinal ulcer (Grade 2) at 1 and 35 months, and one patient (11.1%) developed gastric perforation (Grade 4) at 4 months after proton radiotherapy. CONCLUSIONS: Surgical spacer placement in the locally advanced pancreatic body and tail cancers is relatively safe and technically feasible. Comparing radiation plans, surgical spacer placement seems to improve the dose distribution in the locally advanced pancreatic body and tail cancers, which are close to the gastrointestinal tract.
引用
- Lee D, Komatsu S, Terashima K, et al. Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results. Radiat Oncol. 2021. PMID: 33407648. doi:10.1186/s13014-020-01731-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。